Navigation Links
DURECT Corporation to Participate in Upcoming Healthcare Conferences
Date:9/17/2009

CUPERTINO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

  • Matt Hogan, Chief Financial Officer, will present at the UBS Global Life Sciences Conference in New York on Wednesday, September 23rd at 10:30 a.m. Eastern Time. A live audio webcast of the presentation will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

  • Joe Stauffer, Chief Medical Officer and EVP-Corporate Strategy, will deliver a talk entitled "Issues and Challenges with Clinical Drug Development of Pain Compounds: Failure in Phase III and the Cart before the Horse" at Arrowhead's 3rd Annual Pain Therapeutics Summit in Summit, New Jersey on Friday, September 25th at 8:40 am Eastern Time.

About DURECT

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Announces Sale of 4,444,444 Shares of Common Stock, Raising Proceeds of $10 Million
2. DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)
3. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
4. DURECT Corporation Announces Second Quarter 2009 Financial
5. DURECT to Present at the BMO Capital Markets Healthcare Conference
6. DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call
7. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
8. DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call
9. DURECT to Participate in Cowen and Company Healthcare Conference
10. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
11. DURECT Corporation Invites You to Join Its Fourth Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance and financial planning ... the Cape Coral area, is embarking on a charity drive with the goal of ... The Harry Chapin Food Bank of Southwest Florida works to provide fresh and nutritious ...
(Date:12/8/2016)... ... December 08, 2016 , ... Bill Mull Agencies, a ... in and around central Kansas, is joining the Youth Horizons organization for a ... , Headquartered in Wichita, Youth Horizons works to empower area children from unstable, ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and mental ... mental health systems reform legislation in more than fifty years. We applaud the ... of our elected officials to improving mental health services and supports in our ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a ... smoothing and tightening the skin of the face to create more youthful features. ... with very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Technology, S.L. (“Presence”) for a purchase price of approximately $17.4 million (net ... Presence’s annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... , Dec. 8, 2016 Bodycad announced ... for improving the accuracy, reproducibility and speed for ... long and small bone orthopaedic applications. These patents ... creating personalized orthopaedic restorations based on each patient,s ... restorations, the company harnesses the world,s first suite ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
Breaking Medicine Technology: